Novartis Buying Avexis For 8 7b In Big Gene Therapy Bet Novartis has bought chicago biotech avexis for $8.7 billion, adding a potential gene therapy for the rare disease spinal muscular atrophy (sma) to its pipeline. Swiss drug major novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (sma). the company acquired avexis inc, whose sma gene therapy avxs 101 is in phase iii testing.
Novartis Buying Avexis For 8 7b To Strengthen Gene Therapy Capabilities Novartis has struck an $8.7 billion deal to buy avexis. the move sees newly minted novartis ceo vas narasimhan, m.d., pay a hefty premium to establish the company as a frontrunner in the. Gene therapy developer avexis will be known as novartis gene therapies, more than two years after being acquired by the swiss biopharma giant. in may 2018, novartis spent $8.7 billion to acquire gene therapy technology and therapy developer avexis. Novartis to expand gene therapy pipeline with acquisition of avexis for $8.7 billion – chemical & engineering news. Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash.
Novartis Buys Avexis For 8 7 Billion Novartis to expand gene therapy pipeline with acquisition of avexis for $8.7 billion – chemical & engineering news. Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Novartis has entered into an agreement to acquire avexis, inc, where it will gain the us based nasdaq listed clinical stage gene therapy company for $218 per share ($8.7bn in cash). Tokyo: novartis ag agreed to acquire avexis inc. for $8.7 billion to expand its position in gene therapy with a treatment for a rare disease that afflicts infants. All elements being clearly bearish, it would be possible for traders to trade only short positions (for sale) on novartis n.
Novartis 8 7 Billion Bet On Gene Therapy With Avexis Deal Business Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Novartis has entered into an agreement to acquire avexis, inc, where it will gain the us based nasdaq listed clinical stage gene therapy company for $218 per share ($8.7bn in cash). Tokyo: novartis ag agreed to acquire avexis inc. for $8.7 billion to expand its position in gene therapy with a treatment for a rare disease that afflicts infants. All elements being clearly bearish, it would be possible for traders to trade only short positions (for sale) on novartis n.
Comments are closed.